What are the primary drivers of revenue and profitability for Eli Lilly in Q2 2010?

In Q2 2010, Eli Lilly's revenue and profitability were driven by its portfolio of pharmaceutical products. However, investors should note the significant impact of patent expirations on key drugs, leading to increased generic competition and potential revenue erosion for those specific products. The company's performance would also be influenced by the sales of its newer products and its ability to effectively manage operating expenses.

How is the company addressing the challenges posed by patent expirations?

Eli Lilly's strategy to address patent expirations typically involves a multi-pronged approach. This includes focusing on the growth of its in-line products (those with ongoing patent protection or strong market positions), advancing its robust pipeline of new molecular entities and biologics through research and development, and potentially pursuing strategic acquisitions or partnerships to bolster its future revenue streams.

What should investors look for in the 'Management's Discussion and Analysis' section?

Investors should carefully review the MD&A for a detailed explanation of the company's financial condition and results of operations. Key areas to focus on include year-over-year and sequential changes in revenue and expenses, the factors contributing to these changes (such as product sales, R&D investments, and SG&A costs), commentary on liquidity and capital resources, and management's outlook for future performance and strategic priorities.

Are there any significant legal proceedings or risk factors disclosed that could impact Eli Lilly's financial health?

The 10-Q filing includes sections on Legal Proceedings and Risk Factors. Investors should examine these to understand any ongoing litigation, regulatory investigations, or other potential liabilities that could result in significant financial penalties, reputational damage, or operational disruptions. The risk factors provide insight into potential challenges and uncertainties facing the company.

LLY 10-Q Quarterly Report Q2 FY2010 — Revenue, Net Income, EPS

Summary

Eli Lilly and Company's second quarter 2010 results, as reported in their 10-Q filing dated July 29, 2010, show a company navigating patent expirations while focusing on its pipeline. The company's financial performance during this period requires careful investor consideration, particularly regarding revenue trends and the impact of generic competition on key products. Management's discussion likely centers on strategies to mitigate these challenges and capitalize on future growth opportunities from new drug approvals. Investors should pay close attention to the specific revenue figures for flagship products and the progress of their research and development efforts. The filing will provide insights into Lilly's financial health, liquidity, and any significant legal or regulatory matters that could influence future performance. Understanding these elements is crucial for assessing the company's ability to sustain profitability and deliver shareholder value in the evolving pharmaceutical landscape.

Financial Highlights

47 data points

Beta

Revenue

$5.75B

0.8% Gross Margin

Net Income

$1.35B

0.2% Net Margin

EPS (Diluted)

$1.22

Total Assets

$27.72B

Cash & Equivalents

$5.16B

Free Cash Flow

$1.91B

Financial Statements

Beta

Revenue	$5.75B
Cost of Revenue	$1.02B
Gross Profit	$4.72B
R&D Expenses	$1.19B
SG&A Expenses	$1.76B
Interest Expense	$47.50M
Net Income	$1.35B
EPS (Basic)	$1.22

Key Highlights

1The filing covers the quarterly period ending June 29, 2010, providing a snapshot of Eli Lilly's financial performance and operational status.
2Significant focus is expected on the impact of patent expirations for key drugs and the corresponding increase in generic competition, which can pressure revenue streams.
3Management's Discussion and Analysis (MD&A) is a critical section for investors to understand the company's financial condition, liquidity, and operational results.
4The report likely details revenue and profitability trends, including the performance of established products and any emerging contributions from newer therapies.
5Investors should examine the company's liquidity position and its ability to manage working capital, debt, and capital expenditures.
6Updates on the company's product pipeline, research and development activities, and regulatory progress are crucial for assessing future growth prospects.
7The filing will also address legal proceedings and risk factors, providing transparency on potential challenges and liabilities.

ELI LILLY & Co Quarterly Report for Q2 Ended Jun 30, 2010

Summary

Financial Highlights

Key Highlights

Frequently Asked Questions